A. Arriví

First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study

Eduardo Díaz‐Rubio, Auxiliadora Gómez‐España, Bartomeu Massutí et al. · The Oncologist · 2012 · 212 citations · Full text

Medicine, Oncology, Pharmacology +12

Addition of Bevacizumab to XELOX Induction Therapy Plus Concomitant Capecitabine-Based Chemoradiotherapy in Magnetic Resonance Imaging–Defined Poor-Prognosis Locally Advanced Rectal Cancer: The AVACROSS Study

Miguel Nogué, Antonieta Salud, Pilar Vicente et al. · The Oncologist · 2011 · 155 citations · Full text

Medicine, Oncology, Surgery +17

Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract

Miquel Nogué‐Aliguer, Joan Carles, A. Arriví et al. · Cancer · 2003 · 99 citations · Full text

Medicine, Oncology, Pharmacology +16

Circulating Tumor Cell Count Is a Prognostic Factor in Metastatic Colorectal Cancer Patients Receiving First-Line Chemotherapy Plus Bevacizumab: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study

Javier Sastre, M.L. Maestro, Auxiliadora Gómez‐España et al. · The Oncologist · 2012 · 88 citations · Full text

Medicine, Oncology, Pharmacology +17

Toxic Epidermal Necrolysis in Patients Receiving Anticonvulsants and Cranial Irradiation: A Risk to Consider

David Aguiar, Roberto Pazo, Ignacio Durán et al. · Journal of Neuro-Oncology · 2004 · 79 citations

Medicine, Neurology, Toxicology +15